Zumilokibart (APG777)
Moderate-to-Severe Atopic Dermatitis
Key Facts
About Apogee Therapeutics
Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.
View full company profileAbout Apogee Therapeutics
Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.
View full company profileAbout Apogee Therapeutics
Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| APG279 (Zumilokibart + APG990) | Apogee Therapeutics | Phase 1 |
| ATI-1777 | Aclaris Therapeutics | Phase 2b |